188 related articles for article (PubMed ID: 10589777)
1. BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity.
Gatto C; Rieppi M; Borsotti P; Innocenti S; Ceruti R; Drudis T; Scanziani E; Casazza AM; Taraboletti G; Giavazzi R
Clin Cancer Res; 1999 Nov; 5(11):3603-7. PubMed ID: 10589777
[TBL] [Abstract][Full Text] [Related]
2. Activity of biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in a human breast cancer orthotopic model.
Nozaki S; Sissons S; Chien DS; Sledge GW
Clin Exp Metastasis; 2003; 20(5):407-12. PubMed ID: 14524529
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291.
Naglich JG; Jure-Kunkel M; Gupta E; Fargnoli J; Henderson AJ; Lewin AC; Talbott R; Baxter A; Bird J; Savopoulos R; Wills R; Kramer RA; Trail PA
Cancer Res; 2001 Dec; 61(23):8480-5. PubMed ID: 11731431
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center.
Hotchkiss KA; Ashton AW; Mahmood R; Russell RG; Sparano JA; Schwartz EL
Mol Cancer Ther; 2002 Nov; 1(13):1191-200. PubMed ID: 12479700
[TBL] [Abstract][Full Text] [Related]
5. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies.
Rowinsky EK; Humphrey R; Hammond LA; Aylesworth C; Smetzer L; Hidalgo M; Morrow M; Smith L; Garner A; Sorensen JM; Von Hoff DD; Eckhardt SG
J Clin Oncol; 2000 Jan; 18(1):178-86. PubMed ID: 10623708
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative.
Taraboletti G; Micheletti G; Rieppi M; Poli M; Turatto M; Rossi C; Borsotti P; Roccabianca P; Scanziani E; Nicoletti MI; Bombardelli E; Morazzoni P; Riva A; Giavazzi R
Clin Cancer Res; 2002 Apr; 8(4):1182-8. PubMed ID: 11948131
[TBL] [Abstract][Full Text] [Related]
8. Suppression of human microvascular endothelial cell invasion and morphogenesis with synthetic matrixin inhibitors. Targeting angiogenesis with MMP inhibitors.
Jia MC; Schwartz MA; Sang QA
Adv Exp Med Biol; 2000; 476():181-94. PubMed ID: 10949665
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic activity of beta-eudesmol in vitro and in vivo.
Tsuneki H; Ma EL; Kobayashi S; Sekizaki N; Maekawa K; Sasaoka T; Wang MW; Kimura I
Eur J Pharmacol; 2005 Apr; 512(2-3):105-15. PubMed ID: 15840394
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy.
Pisanti S; Borselli C; Oliviero O; Laezza C; Gazzerro P; Bifulco M
J Cell Physiol; 2007 May; 211(2):495-503. PubMed ID: 17192847
[TBL] [Abstract][Full Text] [Related]
11. Gabexate mesilate inhibits colon cancer growth, invasion, and metastasis by reducing matrix metalloproteinases and angiogenesis.
Yoon WH; Jung YJ; Kim TD; Li G; Park BJ; Kim JY; Lee YC; Kim JM; Park JI; Park HD; No ZS; Lim K; Hwang BD; Kim YS
Clin Cancer Res; 2004 Jul; 10(13):4517-26. PubMed ID: 15240544
[TBL] [Abstract][Full Text] [Related]
12. A novel non-containing-nitrogen bisphosphonate inhibits both in vitro and in vivo angiogenesis.
Hamma-Kourbali Y; Di Benedetto M; Ledoux D; Oudar O; Leroux Y; Lecouvey M; Kraemer M
Biochem Biophys Res Commun; 2003 Oct; 310(3):816-23. PubMed ID: 14550277
[TBL] [Abstract][Full Text] [Related]
13. Lonidamine causes inhibition of angiogenesis-related endothelial cell functions.
Del Bufalo D; Trisciuoglio D; Scarsella M; D'Amati G; Candiloro A; Iervolino A; Leonetti C; Zupi G
Neoplasia; 2004; 6(5):513-22. PubMed ID: 15548359
[TBL] [Abstract][Full Text] [Related]
14. Baicalein and baicalin are potent inhibitors of angiogenesis: Inhibition of endothelial cell proliferation, migration and differentiation.
Liu JJ; Huang TS; Cheng WF; Lu FJ
Int J Cancer; 2003 Sep; 106(4):559-565. PubMed ID: 12845652
[TBL] [Abstract][Full Text] [Related]
15. The angiosuppressive effects of 20(R)- ginsenoside Rg3.
Yue PY; Wong DY; Wu PK; Leung PY; Mak NK; Yeung HW; Liu L; Cai Z; Jiang ZH; Fan TP; Wong RN
Biochem Pharmacol; 2006 Aug; 72(4):437-45. PubMed ID: 16793023
[TBL] [Abstract][Full Text] [Related]
16. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression.
Salcedo R; Ponce ML; Young HA; Wasserman K; Ward JM; Kleinman HK; Oppenheim JJ; Murphy WJ
Blood; 2000 Jul; 96(1):34-40. PubMed ID: 10891427
[TBL] [Abstract][Full Text] [Related]
17. SI-27, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity: detection with a variable-pressure scanning electron microscope.
Yoshida D; Noha M; Watanabe K; Sugisaki Y; Teramoto A
Neurosurgery; 2002 Mar; 50(3):578-86; discussion 586-8. PubMed ID: 11841727
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566.
Erlichman C; Adjei AA; Alberts SR; Sloan JA; Goldberg RM; Pitot HC; Rubin J; Atherton PJ; Klee GG; Humphrey R
Ann Oncol; 2001 Mar; 12(3):389-95. PubMed ID: 11332153
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of angiogenesis by the cancer chemopreventive agent conjugated linoleic acid.
Masso-Welch PA; Zangani D; Ip C; Vaughan MM; Shoemaker S; Ramirez RA; Ip MM
Cancer Res; 2002 Aug; 62(15):4383-9. PubMed ID: 12154044
[TBL] [Abstract][Full Text] [Related]
20. Clotrimazole, an imidazole antimycotic, is a potent inhibitor of angiogenesis.
Takahashi H; Abe M; Sugawara T; Tanaka K; Saito Y; Fujimura S; Shibuya M; Sato Y
Jpn J Cancer Res; 1998 Apr; 89(4):445-51. PubMed ID: 9617351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
